DOP2022000021A - Materiales y métodos para la dirección al receptor de anticuerpos poliméricos - Google Patents
Materiales y métodos para la dirección al receptor de anticuerpos poliméricosInfo
- Publication number
- DOP2022000021A DOP2022000021A DO2022000021A DO2022000021A DOP2022000021A DO P2022000021 A DOP2022000021 A DO P2022000021A DO 2022000021 A DO2022000021 A DO 2022000021A DO 2022000021 A DO2022000021 A DO 2022000021A DO P2022000021 A DOP2022000021 A DO P2022000021A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pigr
- materials
- methods
- receptor targeting
- vhh
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se describen dominios de VHH que se unen al pIgR. El dominio de VHH puede competir con la unión de la IgA al pIgR o, alternativamente, el dominio de VHH puede competir con la unión de la IgA al pIgR. Los dominios de VHH pueden acoplarse a agentes terapéuticos para facilitar el suministro del agente terapéutico a la capa de la mucosa a través de la transcitosis mediada por el pIgR. El agente terapéutico puede ser una molécula pequeña, una molécula grande o, incluso, un anticuerpo.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882387P | 2019-08-02 | 2019-08-02 | |
US201962882346P | 2019-08-02 | 2019-08-02 | |
US201962882291P | 2019-08-02 | 2019-08-02 | |
US201962882361P | 2019-08-02 | 2019-08-02 | |
US201962940208P | 2019-11-25 | 2019-11-25 | |
US201962940196P | 2019-11-25 | 2019-11-25 | |
US201962940206P | 2019-11-25 | 2019-11-25 | |
US201962940228P | 2019-11-25 | 2019-11-25 | |
US201962940220P | 2019-11-25 | 2019-11-25 | |
US201962940200P | 2019-11-25 | 2019-11-25 | |
US201962940232P | 2019-11-25 | 2019-11-25 | |
PCT/US2020/044505 WO2021026000A1 (en) | 2019-08-02 | 2020-07-31 | Materials and methods for polymeric antibody receptor targeting |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2022000021A true DOP2022000021A (es) | 2022-08-15 |
Family
ID=74502941
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000022A DOP2022000022A (es) | 2019-08-02 | 2022-01-28 | Materiales y métodos para el biotransporte multidireccional |
DO2022000021A DOP2022000021A (es) | 2019-08-02 | 2022-01-28 | Materiales y métodos para la dirección al receptor de anticuerpos poliméricos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000022A DOP2022000022A (es) | 2019-08-02 | 2022-01-28 | Materiales y métodos para el biotransporte multidireccional |
Country Status (18)
Country | Link |
---|---|
US (2) | US20230019640A1 (es) |
EP (2) | EP4007607A4 (es) |
JP (2) | JP2022542391A (es) |
KR (2) | KR20220054585A (es) |
CN (2) | CN114173801A (es) |
AU (2) | AU2020326589A1 (es) |
BR (2) | BR112022001352A2 (es) |
CA (2) | CA3147916A1 (es) |
CO (2) | CO2022000817A2 (es) |
CR (2) | CR20220042A (es) |
DO (2) | DOP2022000022A (es) |
EC (2) | ECSP22007690A (es) |
IL (2) | IL289955A (es) |
JO (1) | JOP20220025A1 (es) |
MX (2) | MX2022001278A (es) |
PE (2) | PE20220298A1 (es) |
TW (2) | TW202122108A (es) |
WO (2) | WO2021026000A1 (es) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU728587B2 (en) * | 1996-06-04 | 2001-01-11 | Regents Of The University Of California, The | Cellular internalization of pIgR stalk and associated ligands |
US6060082A (en) * | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
WO2000047611A2 (en) * | 1999-02-12 | 2000-08-17 | Oklahoma Medical Research Foundation | Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor |
EP1268555A2 (en) * | 2000-03-27 | 2003-01-02 | The Regents of The University of California | Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
MXPA03002918A (es) * | 2000-10-02 | 2004-04-20 | Arizeke Pharmaceuticals Inc | Composiciones y metodos para el transporte de agentes biologicamente activos a traves de barreras celulares. |
US20030166160A1 (en) * | 2001-09-06 | 2003-09-04 | Hawley Stephen B. | Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands |
AU2002305140A1 (en) * | 2001-04-03 | 2002-10-28 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions |
AU2004204763A1 (en) * | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
EP2101801A1 (en) * | 2006-12-20 | 2009-09-23 | Ablynx N.V. | Oral delivery of polypeptides |
US20100166734A1 (en) * | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
EP1975178A1 (en) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
WO2009080764A2 (en) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
EP2753644A1 (en) * | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
AU2013201422B2 (en) * | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
EP2917731B1 (en) * | 2012-11-08 | 2019-12-25 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Diagnostic, prognostic, therapeutic and screening protocols |
WO2017172517A1 (en) * | 2016-03-29 | 2017-10-05 | Stcube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
WO2018222506A1 (en) * | 2017-05-27 | 2018-12-06 | Immune-Onc Therapeutics, Inc. | Modulation of immunoglobulin-a-positive cells |
-
2020
- 2020-07-31 EP EP20850058.7A patent/EP4007607A4/en active Pending
- 2020-07-31 MX MX2022001278A patent/MX2022001278A/es unknown
- 2020-07-31 TW TW109126108A patent/TW202122108A/zh unknown
- 2020-07-31 BR BR112022001352A patent/BR112022001352A2/pt not_active Application Discontinuation
- 2020-07-31 JO JOP/2022/0025A patent/JOP20220025A1/ar unknown
- 2020-07-31 CR CR20220042A patent/CR20220042A/es unknown
- 2020-07-31 PE PE2022000180A patent/PE20220298A1/es unknown
- 2020-07-31 CA CA3147916A patent/CA3147916A1/en not_active Abandoned
- 2020-07-31 AU AU2020326589A patent/AU2020326589A1/en active Pending
- 2020-07-31 JP JP2022506123A patent/JP2022542391A/ja active Pending
- 2020-07-31 WO PCT/US2020/044505 patent/WO2021026000A1/en active Application Filing
- 2020-07-31 KR KR1020227003638A patent/KR20220054585A/ko unknown
- 2020-07-31 CN CN202080055485.8A patent/CN114173801A/zh active Pending
- 2020-07-31 TW TW109126094A patent/TW202116813A/zh unknown
- 2020-07-31 PE PE2022000168A patent/PE20220344A1/es unknown
- 2020-07-31 CR CR20220043A patent/CR20220043A/es unknown
- 2020-07-31 CN CN202080061126.3A patent/CN114423451A/zh active Pending
- 2020-07-31 KR KR1020227003585A patent/KR20220054289A/ko unknown
- 2020-07-31 WO PCT/US2020/044497 patent/WO2021025997A1/en active Application Filing
- 2020-07-31 CA CA3147905A patent/CA3147905A1/en not_active Abandoned
- 2020-07-31 US US17/630,706 patent/US20230019640A1/en active Pending
- 2020-07-31 BR BR112022001080A patent/BR112022001080A2/pt not_active Application Discontinuation
- 2020-07-31 US US17/630,718 patent/US20220324970A1/en active Pending
- 2020-07-31 JP JP2022506274A patent/JP2022542418A/ja active Pending
- 2020-07-31 EP EP20849929.3A patent/EP4007591A4/en active Pending
- 2020-07-31 MX MX2022001379A patent/MX2022001379A/es unknown
- 2020-07-31 AU AU2020326590A patent/AU2020326590A1/en active Pending
-
2022
- 2022-01-18 IL IL289955A patent/IL289955A/en unknown
- 2022-01-18 IL IL289956A patent/IL289956A/en unknown
- 2022-01-28 DO DO2022000022A patent/DOP2022000022A/es unknown
- 2022-01-28 DO DO2022000021A patent/DOP2022000021A/es unknown
- 2022-01-28 CO CONC2022/0000817A patent/CO2022000817A2/es unknown
- 2022-01-31 EC ECSENADI20227690A patent/ECSP22007690A/es unknown
- 2022-02-16 CO CONC2022/0001579A patent/CO2022001579A2/es unknown
- 2022-02-24 EC ECSENADI202214913A patent/ECSP22014913A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020015084A2 (es) | Anticuerpos anti-msr1 y métodos de uso de los mismos | |
CL2020000830A1 (es) | Molécula de unión a cd3 que comprende un dominio variable de cadena ligera (vl) y un dominio variable de cadena pesada (vh) capaz de unir un epítope de cd3 humano y de mamíferos no humanos; composición farmacéutica que comprende dicha molécula y su uso. (divisional solicitud 201303329) | |
PE20170767A1 (es) | Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos | |
PE20200757A1 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
CY1117241T1 (el) | Αντισωματα anti-igf | |
CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
CL2012001817A1 (es) | Anticuerpo monoclonal que reconoce epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos, particularmente a los peptidos abeta amiloides solubles polimericos y peptidos abeta amiloides oligomericos; polinucleotidos que codifican dicho anticuerpo; composicion terapeutica que comprende el anticuerpo; uso del anticuerpo para tratar enfermedades y trastornos causados o asociados a las proteinas amiloides (div. sol. 1742-2008). | |
CL2011000117A1 (es) | Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende. | |
AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
AR100680A1 (es) | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos | |
PE20210375A1 (es) | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales | |
PE20211112A1 (es) | Vacunas neumococicas multivalentes | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
AR113429A1 (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t | |
CO2021012705A2 (es) | Anticuerpos anti-egfrviii y fragmentos de unión a antígeno de los mismos | |
CY1123968T1 (el) | Enanti-cd71 ενεργοποιουμενα συζευγματα αντισωματος φαρμακου και μεθοδοι χρησης αυτων | |
MX2021004058A (es) | Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos. | |
CL2018000131A1 (es) | Inmunoconjugados de il22 | |
PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
CL2023001966A1 (es) | Conjugados de anticuerpo dirigido a b7-h4 y fármaco, y métodos de uso de los mismos | |
AR114437A1 (es) | Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos | |
UY39468A (es) | Materiales y métodos biosintéticos para el biotransporte multidireccional | |
ECSP22014913A (es) | Materiales y métodos para el direccionamiento al receptor de anticuerpos poliméricos |